ACADIA Pharmaceuticals ( (ACAD) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ACADIA Pharmaceuticals shares are jumping after investors reacted to fresh optimism around the drugmaker’s core business and future pipeline. The company has held up well despite macro pressures and a regulatory setback in Europe, while sales of its flagship drug Nuplazid remain solid.
BofA Securities fueled the rally by upgrading ACADIA from “Neutral” to “Buy,” arguing that a recent 25% pullback left the stock trading at an attractive valuation. The bank reaffirmed its $29.00 price target, pointing to potential upside from the company’s clinical programs as a key reason for its bullish stance.
More about ACADIA Pharmaceuticals
YTD Price Performance: -21.53%
Average Trading Volume: 1,606,222
Technical Sentiment Signal: Sell
Current Market Cap: $3.58B
For further insights into ACAD stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.